One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
JCO Turns 40.
Miller, Kathy D. MD 1,2,; Friedberg, Jonathan W. MD 2,3,4,,
doi : 10.1200/JCO.22.02480
Volume 41(1) pgs. 1-150 January 1, 2023
Economic Analysis of Screening, Diagnostic, and Treatment Technologies for Cancer: Reflections and a Roadmap for Prospective Authors.
Ramsey, Scott D. MD, PhD 1,2,,; Friedberg, Jonathan W. MD 3,; Cox, John V. DO 4,; Peppercorn, Jeffrey M. MD, MPH 5,
doi : 10.1200/JCO.22.01556
Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert?.
Plimack, Elizabeth R. MD, MS 1,,; Zibelman, Matthew R. MD 1,
doi : 10.1200/JCO.22.01992
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Regulation of Laboratory-Developed Tests in Preventive Oncology: Emerging Needs and Opportunities.
Offit, Kenneth MD, MPH 1,2,,; Sharkey, Catherine M. JD, MSc 3; Green, Dina MA, MS 1; Wu, Xiaohan MPH, JD 4; Trottier, Magan MSc 1; Hamilton, Jada G. PhD, MPH 1,2; Walsh, Michael F. MD 1,2; Dandiker, Sita MS 1; Belhadj, Sami PhD 1; Lipkin, Steven M. MD, PhD 2; Sugranes, Thelma Alessandra MD 5; Caggana, Michele ScD 6,; Stadler, Zsofia K. MD 1,2,
doi : 10.1200/JCO.22.00995
AB Cancer predictive or diagnostic assays, offered as Laboratory-Developed Tests (LDTs), have been subject to regulatory authority and enforcement discretion by the US Food and Drug Administration.
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Hoimes, Christopher J. DO 1,2,; Flaig, Thomas W. MD 3,; Milowsky, Matthew I. MD 4,; Friedlander, Terence W. MD 5,; Bilen, Mehmet Asim MD 6,; Gupta, Shilpa MD 7,; Srinivas, Sandy MD 8,; Merchan, Jaime R. MD 9,; McKay, Rana R. MD 10,; Petrylak, Daniel P. MD 11,; Sasse, Carolyn BS 12,; Moreno, Blanca Homet MD, PhD 13,; Yu, Yao PhD 14,; Carret, Anne-Sophie MD 14,; Rosenberg, Jonathan E. MD 15,,
doi : 10.1200/JCO.22.01643
Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely durable, and many patients with la/mUC are ineligible.
Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
Wheeler, Stephanie B. PhD, MPH 1,2,3,,; Rotter, Jason PhD 1; Gogate, Anagha PhD 1,; Reeder-Hayes, Katherine E. MD, MBA, MSc 2,4,; Drier, Sarah W. MPH 2; Ekwueme, Donatus U. PhD, MS 5; Fairley, Temeika L. PhD 5; Rocque, Gabrielle B. MD 6,; Trogdon, Justin G. PhD 1,2,3
doi : 10.1200/JCO.21.02473
Treatments for endocrine-refractory or triple-negative metastatic breast cancer (mBC) are modestly effective at prolonging life and improving quality of life but can be extremely expensive.
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
Rosenberg, Jonathan E. MD 1,,; Park, Se Hoon MD, PhD 2,; Kozlov, Vadim MD 3; Dao, Tu V. MD, PhD 4,; Castellano, Daniel MD 5,; Li, Jian-Ri MD, PhD 6; Mukherjee, Som D. MD 7,; Howells, Kathryn MSc 8,; Dry, Hannah BSc 9,; Lanasa, Mark C. MD, PhD 9,; Stewart, Ross PhD 8,; Bajorin, Dean F. MD 1,
doi : 10.1200/JCO.22.00205
Homologous recombination repair gene mutations (HRRm) are common in urothelial carcinoma (UC), rendering tumor cells sensitive to poly (ADP-ribose) polymerase (PARP) inhibition.
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
Crabb, Simon J. PhD, MBBS 1,,; Hussain, Syed MD 2,; Soulis, Eileen MA 3; Hinsley, Samantha MSc 3; Dempsey, Laura MSc 3; Trevethan, Avril 3; Song, YeePei MRCP 4,; Barber, Jim MRCP 5; Frew, John MRCP 6,; Gale, Joanna MRCP 7; Faust, Guy MRCP 8,; Brock, Susannah FRCR 9; McGovern, Ursula MRCP 10,; Parikh, Omi MRCP 11,; Enting, Deborah MRCP 12,; Sundar, Santhanam MRCP 13,; Ratnayake, Gihan MRCP 14,; Lees, Kathryn MRCP 15; Birtle, Alison J. MRCP 16,; Powles, Thomas MRCP 17,; Jones, Robert J. PhD 3,
doi : 10.1200/JCO.22.00405
A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. We tested switch maintenance therapy with the poly ADP-ribose polymerase inhibitor rucaparib, following chemotherapy, for DRD biomarker-positive mUC.
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
Rugo, Hope S. MD 1,,; Umanzor, Gerardo A. MD 2; Barrios, Francisco J. MD 3; Vasallo, Rosa H. MD 4,; Chivalan, Marco A. MD 5; Bejarano, Suyapa MD 6,; Ramirez, Julio R. MD 7,; Fein, Luis MD 8,; Kowalyszyn, Ruben D. MD 9,; Kramer, E. Douglas MD 10,; Wang, Hui PhD 10,; Kwan, Min-Fun R. MB, BS 10,; Cutler, David L. MD 10,; for the Oraxol Study Consortium Investigators
doi : 10.1200/JCO.21.02953
Intravenous paclitaxel (IVpac) is complicated by neuropathy and requires premedication to prevent hypersensitivity-type reactions. Paclitaxel is poorly absorbed orally; encequidar (E), a novel P-glycoprotein pump inhibitor, allows oral absorption.
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Arance, Ana MD, PhD 1,,; de la Cruz-Merino, Luis MD, PhD 2,; Petrella, Teresa M. MD 3,; Jamal, Rahima MD 4,; Ny, Lars MD, PhD 5,; Carneiro, Ana MD, PhD 6,; Berrocal, Alfonso MD 7,; Marquez-Rodas, Ivan MD, PhD 8,; Spreafico, Anna MD, PhD 9,; Atkinson, Victoria MD 10,; Costa Svedman, Fernanda MD, PhD 11,; Mant, Andrew MBBS 12,; Khattak, Muhammad A. MBBS, FRACP 13; Mihalcioiu, Catalin MD 14,; Jang, Sekwon MD 15,; Cowey, C. Lance MD 16,; Smith, Alan D. MD 17,; Hawk, Natalyn MD, PhD 18,; Chen, Ke MS 19,; Diede, Scott J. MD, PhD 19,; Krepler, Clemens MD 19,; Long, Georgina V. MBBS, PhD 20,21,22,23,
doi : 10.1200/JCO.22.00221
Effective treatments are needed for melanoma that progresses on inhibitors of programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II LEAP-004 study to evaluate the combination of the multikinase inhibitor lenvatinib and the PD-1 inhibitor pembrolizumab in this population (ClinicalTrials.gov identifier: NCT03776136).
Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma.
de Vries, Simone MSc 1; Haaksma, Miriam L. PhD 2; Jozwiak, Katarzyna PhD 3; Schaapveld, Michael PhD 1; Hodgson, David C. MD, PhD 4; Lugtenburg, Pieternella J. MD, PhD 5,; Krol, Augustinus D.G. MD, PhD 6; Petersen, Eefke J. MD, PhD 7; van Spronsen, Dick Johan MD, PhD 8; Ahmed, Sameera MSc 4; Hauptmann, Michael PhD 3; Aleman, Berthe M.P. MD, PhD 9; van Leeuwen, Flora E. PhD 1,
doi : 10.1200/JCO.21.02613
Previous efforts to predict absolute risk of treatment-related cardiovascular diseases (CVDs) have mostly focused on childhood cancer survivors. We aimed to develop prediction models for risk of coronary heart disease (CHD) and heart failure (HF) for survivors of adolescent/adult Hodgkin lymphoma (HL).
Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study.
de Baat, Esmee C. MD 1,; Feijen, Elizabeth A.M. PhD 1; Reulen, Raoul C. PhD 2; Allodji, Rodrigue S. PhD 3,4,5; Bagnasco, Francesca PhD 6; Bardi, Edit MD, PhD 7,8; Belle, Fabien N. PhD 9,10; Byrne, Julianne PhD 11; van Dalen, Elvira C. MD, PhD 1; Debiche, Ghazi PhD 3,4,5; Diallo, Ibrahima PhD 3,4,5; Grabow, Desiree PhD 12; Hjorth, Lars MD, PhD 13,; Jankovic, Momcilo MD, PhD 14; Kuehni, Claudia E. MD, PhD 9,15; Levitt, Gill MD, PhD 16; Llanas, Damien MSc 3,4,5; Loonen, Jacqueline MD, PhD 17; Zaletel, Lorna Z. MD, PhD 18; Maule, Milena M. PhD 19; Miligi, Lucia PhD 20; van der Pal, Helena J.H. MD, PhD 1; Ronckers, Cecile M. PhD 1; Sacerdote, Carlotta PhD 19; Skinner, Roderick MD, PhD 21,22; Jakab, Zsuzsanna MD, PhD 23; Veres, Cristina MSc 3,4,5; Haddy, Nadia PhD 3,4,5; Winter, David L. MSc 2; de Vathaire, Florent PhD 3,4,5; Hawkins, Michael M. PhD 2; Kremer, Leontien C.M. MD, PhD 1,24
doi : 10.1200/JCO.21.02944
Heart failure (HF) is a potentially life-threatening complication of treatment for childhood cancer. We evaluated the risk and risk factors for HF in a large European study of long-term survivors.
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
You, Benoit MD, PhD 1,2,,; Sehgal, Vasudha PhD 3; Hosmane, Balakrishna PhD 3,; Huang, Xin PhD 3,; Ansell, Peter J. PhD 3,; Dinh, Minh H. MD 3,; Bell-McGuinn, Katherine MD, PhD 3,; Luo, Xizhi PhD 3,; Fleming, Gini F. MD 4,; Friedlander, Michael PhD 5,; Bookman, Michael A. MD 6,; Moore, Kathleen N. MD 7,; Steffensen, Karina D. MD, PhD 8,; Coleman, Robert L. MD 9,; Swisher, Elizabeth M. MD 10,
doi : 10.1200/JCO.22.00430
In VELIA trial, veliparib combined with carboplatin-paclitaxel, followed by maintenance (veliparib-throughout) was associated with improved progression-free survival (PFS) compared with carboplatin-paclitaxel alone in patients with high-grade ovarian carcinomas.
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
Peng, Zhenwei MD, PhD 1,2; Fan, Wenzhe MD 3; Zhu, Bowen MSc 3; Wang, Guoying MD 4; Sun, Junhui MD 5; Xiao, Chengjiang MSc 6; Huang, Fuxi MSc 7; Tang, Rong MSc 8; Cheng, Yu MSc 9; Huang, Zhen MSc 10; Liang, Yuchuang MSc 11; Fan, Huishuang MSc 12; Qiao, Liangliang MSc 13; Li, Fuliang MSc 14; Zhuang, Wenquan MD 15; Peng, Baogang MD 16; Wang, Jiping MD, PhD 17,; Li, Jiaping MD 3; Kuang, Ming MD, PhD 1,16,
doi : 10.1200/JCO.22.00392
Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to compare clinical outcomes of LEN combined with transarterial chemoembolization (LEN-TACE) versus LEN monotherapy in patients with advanced HCC.
Mudras in Medicine: A Role for Dance in Appreciating Nonverbal Communication in the Clinical Encounter.
Bharadwaj, Maheetha MD, MS, MPhil 1,2; Nagda, Dipal MPH 1; Goyal, Lipika MD, MPhil 3,,
doi : 10.1200/JCO.22.00657
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria.
Gurnari, Carmelo MD 1,2; Pagliuca, Simona MD, PhD 1,3; Prata, Pedro Henrique MD 4,5,6,7; Galimard, Jacques-Emmanuel PhD 8; Catto, Luiz Fernando B. MD 6; Larcher, Lise PhD 4,5; Sebert, Marie MD, PhD 5,9,; Allain, Vincent MD 4,10; Patel, Bhumika J. MD 1,; Durmaz, Arda BSc 1; Pinto, Andre L. MSc 6; Inacio, Mariana C.B. MD 6; Hernandez, Lucie 4,5; Dhedin, Nathalie MD 11; Caillat-Zucman, Sophie MD 4,10,; Clappier, Emmanuelle PhD 5; Sicre de Fontbrune, Flore MD 7,12,; Voso, Maria Teresa MD 2,; Visconte, Valeria PhD 1; Peffault de Latour, Regis MD, PhD 4,7,12,; Soulier, Jean MD, PhD 4,5,; Calado, Rodrigo T. MD, PhD 6,; Socie, Gerard MD, PhD 4,7,12,13,; Maciejewski, Jaroslaw P. MD, PhD 1,,
doi : 10.1200/JCO.22.00710
Secondary myeloid neoplasms (sMNs) remain the most serious long-term complications in patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH). However, sMNs lack specific predictors, dedicated surveillance measures, and early therapeutic interventions.
Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology.
Lv, Meng PhD candidate; Luo, Xufei MPH; Chen, Yaolong MD, PhD
doi : 10.1200/JCO.22.01061
Reply to M. Lv et al.
Singleton, Anna C. PhD; Raeside, Rebecca MPH; Hyun, Karice K. PhD; Partridge, Stephanie R. PhD; Di Tanna, Gian Luca PhD; Hafiz, Nashid MIPH; Tu, Qiang PhD; Tat-Ko, Justin BMSc; Sum, Stephanie Che Mun BMSc, PhD; Sherman, Kerry A. PhD; Elder, Elisabeth PhD; Redfern, Julie PhD
doi : 10.1200/JCO.22.01571
TP53 Gene Indels Impact on Cancer Outcomes.
Guerra, Emanuela PhD; Alberti, Saverio MD, PhD
doi : 10.1200/JCO.22.01385
We All Seem to Agree: Exercise Is Medicine in Medical Oncology.
Campbell, Kristin L. PhD; Winters-Stone, Kerri M. PhD; Schmitz, Kathryn H. PhD, MPH
doi : 10.1200/JCO.22.01448
Reply to K.L. Campbell et al.
Ligibel, Jennifer A. MD; Bohlke, Kari ScD; Alfano, Catherine M. PhD
doi : 10.1200/JCO.22.01722
